Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

Calendar

08-25 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
28/07/26	CN¥4.570	-0.65%	7,917,210
27/07/26	CN¥4.600	+2.22%	9,920,092
24/07/26	CN¥4.500	-4.26%	12,149,082
23/07/26	CN¥4.700	+0.86%	12,455,763
22/07/26	CN¥4.660	-0.43%	13,679,391

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 28/07/2026			5-day change	1st Jan Change
4.570 ^CNY	-0.65%		-2.35%	-12.45%

06-15	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	6.52B 964M 846M 787M 724M 1.36B 92.05B 1.38B 9.34B 3.66B 45.65B 3.62B 3.54B 158B	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	5.03B 743M 652M 607M 559M 1.05B 71.01B 1.07B 7.21B 2.82B 35.22B 2.79B 2.73B 122B	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.51%	Yield 2024	1.9%	Yield 2025	1.05%

06-15	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
04-27	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-02	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-01	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
27/10/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/10/25	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/09/25	Northeast Pharmaceutical Appoints CFO	MT
02/09/25	Northeast Pharmaceutical CFO Resigns	MT
26/08/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/06/25	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/04/25	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Northeast Pharmaceutical Group Co., Ltd. Announces Directorate Appointments	CI
25/04/25	Northeast Pharmaceutical Group Co., Ltd. Approves Cash Dividend on (A Shares) for 2024, Payable on 23 June 2025	CI

1 day	-0.65%
1 week	-2.35%
Current month	+7.78%
1 month	+8.81%
3 months	-7.68%
6 months	-15.37%
Current year	-12.45%

Northeast Pharmaceutical Group Co., Ltd. Share Price

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news : Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.47	4.71
1 month	4.17	4.94
Current year	4.09	5.73
1 year	4.09	6.39
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	20/01/2025
Xin Li DFI	Director of Finance/CFO	46	05/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	30/06/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	20/01/2025
Zhi Hua Huang BRD	Director/Board Member	58	16/11/2021
Cheng Ren Huang BRD	Director/Board Member	62	17/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/22	Zhengwei	Buy		36,000	0.0027%
26/05/22	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/05/22	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	7.5B 1.11B 973M 906M 833M 1.56B 106B 1.59B 10.75B 4.21B 52.52B 4.16B 4.07B 181B	7.07B 1.05B 917M 854M 786M 1.47B 99.86B 1.5B 10.13B 3.97B 49.52B 3.92B 3.84B 171B
Net income	410M 60.55M 53.14M 49.48M 45.51M 85.32M 5.78B 86.78M 587M 230M 2.87B 227M 222M 9.91B	260M 38.42M 33.72M 31.4M 28.88M 54.14M 3.67B 55.07M 373M 146M 1.82B 144M 141M 6.29B
Net Debt	-2.88B -425M -373M -347M -319M -599M -40.59B -609M -4.12B -1.61B -20.13B -1.59B -1.56B -69.55B	-1.49B -220M -193M -180M -166M -310M -21.04B -316M -2.13B -836M -10.43B -827M -809M -36.05B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	-0.65%	-2.35%	-28.93%	-14.74%	969M
ELI LILLY AND COMPANY	+1.93%	+3.85%	+51.05%	+166.24%	1,068B
JOHNSON & JOHNSON	+0.29%	+6.43%	+60.47%	+52.87%	641B
ABBVIE INC.	+2.45%	+2.77%	+39.61%	+74.48%	454B
ROCHE HOLDING AG	+2.17%	+10.22%	+41.17%	+36.56%	351B
NOVARTIS AG	+1.46%	+3.87%	+39.70%	+44.49%	299B
ASTRAZENECA PLC	+0.40%	+3.59%	+19.93%	+17.02%	266B
NOVO NORDISK A/S	+2.73%	+3.50%	-25.66%	-36.53%	220B
AMGEN INC.	+4.48%	+7.33%	+30.47%	+66.31%	203B
GILEAD SCIENCES, INC.	+2.91%	+3.10%	+18.84%	+74.76%	162B
Average	+1.90%	+3.86%	+24.67%	+48.15%	366.43B
Weighted average by Cap.	+1.96%	+4.79%	+39.96%	+80.07%